Prescription delayed-release capsules for relapsing forms of multiple sclerosis that reduce relapse rate
Fumarox (Dimethyl Fumarate) is a delayed-release capsule approved for treating relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS (RRMS) and active secondary progressive MS. It reduces relapse rates and slows disease progression with neuroprotective effects.
Key Features:
• Decreases relapse rate
• Slows MS progression
• Effective in early and active disease
Warnings: Contraindicated in patients allergic to DMF or any of its components. Discontinue immediately if symptoms of anaphylaxis (e.g., swelling, difficulty breathing) occur. May cause lymphopenia, opportunistic infections (e.g., herpes zoster), liver injury and flushing. Suspend treatment if PML is suspected. Common side effects: flushing, abdominal pain, diarrhea, nausea. CBC (lymphocyte count) and liver enzymes must be checked before and during therapy. Store at room temperature away from moisture and direct light. This is a prescription medicine; use only under a physician's supervision.
Size: 60 capsules
Attributes
Product Content
How to Use:
• Initial dose (120 mg): one capsule twice daily for 7 days
• Maintenance dose (240 mg): one capsule twice daily thereafter
• Can be taken with or without food
The link to Fumarox 240 mg 60 Delayed Release Capsules has been copied